Relationship Between Renal Function and the Incidence of Adverse Events in Patients With Colorectal Cancer Receiving Oxaliplatin

被引:9
|
作者
Watanabe, Daichi [1 ]
Fujii, Hironori [1 ]
Yamada, Yunami [1 ]
Iihara, Hirotoshi [1 ]
Ishihara, Takuma [2 ]
Matsuhashi, Nobuhisa [3 ]
Takahashi, Takao [3 ]
Yoshida, Kazuhiro [3 ]
Suzuki, Akio [1 ]
机构
[1] Gifu Univ Hosp, Dept Pharm, Yanagido 1-1, Gifu 5011194, Japan
[2] Gifu Univ, Gifu Univ Hosp, Innovat & Clin Res Promot Ctr, Gifu, Japan
[3] Gifu Univ, Dept Surg Oncol, Grad Sch Med, Gifu, Japan
关键词
Oxaliplatin; creatinine clearance; adverse events; colorectal cancer; nausea; CAPECITABINE PLUS OXALIPLATIN; III COLON-CANCER; PHASE-III; 1ST-LINE TREATMENT; ADJUVANT TREATMENT; FLUOROURACIL; LEUCOVORIN; PHARMACOKINETICS; THERAPY; CHEMOTHERAPY;
D O I
10.21873/anticanres.13953
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background/Aim: To clarify whether renal dysfunction affects the incidence of adverse events associated with oxaliplatin, the present study was designed to investigate the relationship between creatinine clearance (Ccr) and the incidence of oxaliplatin-related adverse events. Patients and Methods: A total of 287 CRC patients who received the first cycle of oxaliplatin-based chemotherapy were eligible. Adverse events, including nausea, vomiting, neutropenia and thrombocytopenia, were graded, and the relationship between Ccr and the incidence of adverse events was examined using multivariable logistic regression analysis. Results: A multivariable analysis indicated that the incidence of grade >= 2 nausea increased, while the incidence of other adverse events tended to be higher, as the Ccr decreased. Particularly, renal dysfunction (Ccr <60 ml/min) was a significant risk factor for grade >= 2 nausea (p=0.042). Conclusion: Care should be taken to avoid adverse events associated with oxaliplatin in patients with renal dysfunction.
引用
收藏
页码:299 / 304
页数:6
相关论文
共 50 条
  • [1] Dose Adjustment of Oxaliplatin Based on Renal Function in Patients With Metastatic Colorectal Cancer
    Watanabe, Daichi
    Fujii, Hironori
    Matsuhashi, Nobuhisa
    Iihara, Hirotoshi
    Yamada, Yunami
    Ishihara, Takuma
    Takahashi, Takao
    Yoshida, Kazuhiro
    Suzuki, Akio
    ANTICANCER RESEARCH, 2020, 40 (04) : 2379 - 2386
  • [2] Treatment related severe and fatal adverse events with cetuximab in colorectal cancer patients: a meta-analysis
    Zhang, Di
    Ye, Junjie
    Xu, Tangpeng
    Xiong, Bin
    JOURNAL OF CHEMOTHERAPY, 2013, 25 (03) : 170 - 175
  • [3] Adjuvant Capecitabine and Oxaliplatin for Elderly Patients with Colorectal Cancer
    Okamoto, Kazuaki
    Nozawa, Hiroaki
    Emoto, Shigenobu
    Murono, Koji
    Sasaki, Kazuhito
    Ishihara, Soichiro
    ONCOLOGY, 2022, 100 (11) : 576 - 582
  • [4] Rechallenge with oxaliplatin and peripheral neuropathy in colorectal cancer patients
    Besora, Sarah
    Santos, Cristina
    Izquierdo, Cristina
    Mercedes Martinez-Villacampa, Maria
    Bruna, Jordi
    Velasco, Roser
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2018, 144 (09) : 1793 - 1801
  • [5] Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab
    Tebbutt, N. C.
    Murphy, F.
    Zannino, D.
    Wilson, K.
    Cummins, M. M.
    Abdi, E.
    Strickland, A. H.
    Lowenthal, R. M.
    Marx, G.
    Karapetis, C.
    Shannon, J.
    Goldstein, D.
    Nayagam, S. S.
    Blum, R.
    Chantrill, L.
    Simes, R. J.
    Price, T. J.
    ANNALS OF ONCOLOGY, 2011, 22 (08) : 1834 - 1838
  • [6] Skin platinum deposition in colorectal cancer patients following oxaliplatin-based therapy
    Cao, Yanshuo
    Chang, Qing
    Zhang, Wenjiang
    Ornatsky, Olga
    Hedley, David
    Chen, Eric X.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (06) : 1195 - 1200
  • [7] Analysis of Adverse Events of Bevacizumab-containing Systemic Chemotherapy for Metastatic Colorectal Cancer in Japan
    Isobe, Taichi
    Uchino, Keita
    Makiyama, Chinatsu
    Ariyama, Hiroshi
    Arita, Shuji
    Tamura, Shingo
    Komoda, Masato
    Kusaba, Hitoshi
    Shirakawa, Tsuyoshi
    Esaki, Taito
    Mitsugi, Kenji
    Takaishi, Shigeo
    Akashi, Koichi
    Baba, Eishi
    ANTICANCER RESEARCH, 2014, 34 (04) : 2035 - 2040
  • [8] Risk of Thromboembolic Events and Major Adverse Cardiovascular Events Following Antivascular Endothelial Growth Factor Therapy in Patients with Colorectal Cancer
    Chen, Yen-Cheng
    Yeh, Liang-Tsai
    Yang, Shun-Fa
    Chou, Ming-Chih
    Huang, Jing-Yang
    Yeh, Chao-Bin
    CANCERS, 2023, 15 (01)
  • [9] Phase I drug-interaction study of effects of calcium and magnesium infusions on oxaliplatin pharmacokinetics and acute neurotoxicity in colorectal cancer patients
    Han, Catherine H.
    Khwaounjoo, Prashannata
    Kilfoyle, Dean H.
    Hill, Andrew
    McKeage, Mark J.
    BMC CANCER, 2013, 13
  • [10] Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy
    Hesketh, Paul J.
    Sanz-Altamira, Pedro
    Bushey, Julie
    Hesketh, Ann M.
    SUPPORTIVE CARE IN CANCER, 2012, 20 (05) : 1043 - 1047